160 related articles for article (PubMed ID: 12499470)
21. Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues.
Gold R; Stangel M; Dalakas MC
Nat Clin Pract Neurol; 2007 Jan; 3(1):36-44. PubMed ID: 17205073
[TBL] [Abstract][Full Text] [Related]
22. Treatment of immune-mediated, dysimmune neuropathies.
Finsterer J
Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
[TBL] [Abstract][Full Text] [Related]
23. Off-label use reimbursement.
Cohen J; Wilson A; Faden L
Food Drug Law J; 2009; 64(2):391-403. PubMed ID: 19999289
[TBL] [Abstract][Full Text] [Related]
24. [High Dose Intravenous Immunoglobulin Therapy for Autoimmune Diseases of the Central Nervous System].
Uzawa A; Kuwabara S
Brain Nerve; 2021 May; 73(5):420-424. PubMed ID: 34006671
[TBL] [Abstract][Full Text] [Related]
25. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.
Kaveri SV; Dietrich G; Hurez V; Kazatchkine MD
Clin Exp Immunol; 1991 Nov; 86(2):192-8. PubMed ID: 1934588
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases.
Dalakas MC
Neurology; 1998 Dec; 51(6 Suppl 5):S2-8. PubMed ID: 9851723
[TBL] [Abstract][Full Text] [Related]
27. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature.
Darabi K; Abdel-Wahab O; Dzik WH
Transfusion; 2006 May; 46(5):741-53. PubMed ID: 16686841
[TBL] [Abstract][Full Text] [Related]
28. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review.
Danieli MG; Gelardi C; Pedini V; Moretti R; Gabrielli A; Logullo F
Autoimmun Rev; 2014 Dec; 13(12):1182-8. PubMed ID: 25172241
[TBL] [Abstract][Full Text] [Related]
29. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy for autoimmune autonomic ganglionopathy.
Iodice V; Kimpinski K; Vernino S; Sandroni P; Low PA
Auton Neurosci; 2009 Mar; 146(1-2):22-5. PubMed ID: 19056323
[TBL] [Abstract][Full Text] [Related]
31. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders.
Souayah N; Hasan A; Khan HM; Yacoub HA; Jafri M
J Clin Neuromuscul Dis; 2011 Jun; 12 Suppl 4():S1-10. PubMed ID: 22361589
[TBL] [Abstract][Full Text] [Related]
32. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.
Hachulla E; Benveniste O; Hamidou M; Mouthon L; Schleinitz N; Lozeron P; Léger JM; Vial C; Viala K
Int J Neurosci; 2017 Jun; 127(6):516-523. PubMed ID: 27412148
[TBL] [Abstract][Full Text] [Related]
33. Clinical indications for intravenous immunoglobulin utilization in a tertiary medical center: a 9-year retrospective study.
Shemer A; Kivity S; Shoenfeld Y
Transfusion; 2018 Feb; 58(2):430-438. PubMed ID: 29193136
[TBL] [Abstract][Full Text] [Related]
34. Intravenous immunoglobulin therapy in neurological diseases during pregnancy.
Ringel I; Zettl UK
J Neurol; 2006 Sep; 253 Suppl 5():V70-4. PubMed ID: 16998758
[TBL] [Abstract][Full Text] [Related]
35. [Clinical, electrophysiological and immunological evaluation of the response to treatment with intravenous immunoglobulins in several immune-mediated neuropathies].
Larrodé-Pellicer P; Salgado-Alvarez de Sotomayor F; Iñíguez-Martínez C; Santos S; Tejero-Juste C; Pascual-Millán LF
Rev Neurol; 2005 Mar 16-31; 40(6):345-50. PubMed ID: 15795870
[TBL] [Abstract][Full Text] [Related]
36. Therapy with intravenous immunoglobulins: complications and side-effects.
Wittstock M; Benecke R; Zettl UK
Eur Neurol; 2003; 50(3):172-5. PubMed ID: 14530624
[TBL] [Abstract][Full Text] [Related]
37. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin.
Rütter A; Luger TA
J Am Acad Dermatol; 2001 Jun; 44(6):1010-24. PubMed ID: 11369915
[TBL] [Abstract][Full Text] [Related]
38. Unlabeled uses of intravenous immune globulin.
Leong H; Stachnik J; Bonk ME; Matuszewski KA
Am J Health Syst Pharm; 2008 Oct; 65(19):1815-24. PubMed ID: 18796422
[TBL] [Abstract][Full Text] [Related]
39. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies.
Lehmann HC; Hartung HP
J Neuroimmunol; 2011 Feb; 231(1-2):61-9. PubMed ID: 21056913
[TBL] [Abstract][Full Text] [Related]
40. Mammography coding and reimbursement.
Odle TG
Radiol Technol; 2003; 74(5):385-404; quiz 405-12. PubMed ID: 12800568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
